Clinical trial NCT06304415: Elevated Lipoprotein(a) in Hospital Staff
Official title: Investigating The Prevalence and Clinical Significance of Elevated Lipoprotein(a) Blood Levels in Hospital Staff
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hypercholesterolemia
Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia
Cardiovascular Diseases
Lead sponsor: Changi General Hospital
Sponsor class: OTHER
First posted: 2024-03-12
Enrollment: 2800
Sex: ALL
Minimum age (years): 21
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Working general population

Brief summary: The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population.

Detailed description: The objective of this study is to investigate the prevalence of elevated lipoprotein(a) concentrations and distribution of lipoprotein(a) in a working general population. This is a prospective study investigating the association of lipoprotein(a) with cardiovascular markers and outcomes.

Eligibility criteria: Inclusion Criteria:

1. Any healthcare workers working in healthcare settings (regardless of PHI and/or private setting) aged 21 and above OR family member such as father, mother, siblings, grandparents, spouse and children aged 12 and above of recruited staff with high Lpa ≥120nmol/l
2. Study team members can also be recruited because we are trying to find the prevalence of elevated Lp(a)

Exclusion Criteria:

1. Inability to provide informed consent.
2. Pregnant women.
3. Prisoner

Primary outcomes:
measure: Distribution and prevalence of elevated Lipoprotein(a)
timeFrame: 3 years
Secondary outcomes:
measure: Correlation of lipoprotein(a) with cardiovascular outcomes
timeFrame: 10 years
measure: Genetic variants of lipoprotein(a) and cardiovascular outcomes atherosclerotic events
timeFrame: 10 years
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Clinical Trials & Research Unit
Study officials:
affiliation: Singhealth Foundation
name: Loh Wann Jia
role: PRINCIPAL_INVESTIGATOR
References:
citation: Loh WJ, Watts GF. Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle? Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):94-102. doi: 10.1097/MED.0000000000000789. Epub 2022 Dec 5.
citation: Loh WJ, Chang X, Aw TC, Phua SK, Low AF, Chan MY, Watts GF, Heng CK. Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population. Atherosclerosis. 2022 May;349:160-165. doi: 10.1016/j.atherosclerosis.2021.11.018. Epub 2021 Nov 26.
citation: Loh WJ, Chan DC, Mata P, Watts GF. Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Front Genet. 2022 Apr 27;13:905941. doi: 10.3389/fgene.2022.905941. eCollection 2022.
citation: Nestel P, Loh WJ, Ward NC, Watts GF. New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. J Clin Endocrinol Metab. 2022 Nov 23;107(11):e4281-e4294. doi: 10.1210/clinem/dgac541.
citation: Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgozoglu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361.